Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer

被引：0
|
作者：
C. E. Henry
E. Llamosas
A. Djordjevic
N. F. Hacker
C. E. Ford
机构：
[1] University of New South Wales,Adult Cancer Program, Level 2, Metastasis Research Group, Lowy Cancer Research Centre and School of Women’s and Children’s Health, Faculty of Medicine
[2] University of New South Wales,Gynaecological Cancer Centre, Royal Hospital for Women, Sydney and School of Women’s and Children’s Health, Faculty of Medicine
来源：
Oncogenesis | / 11卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Expression of ROR1 and ROR2 in Hairy Cell Leukemia Cells Enhances Constitutive Activation of ERK1/2 and Cancer Stemness
    Widhopf II, George F.
    Ghia, Emanuela M.
    Cring, Matthew R.
    Kipps, Thomas J.
    BLOOD, 2024, 144 : 744 - 744
  • [32] ROR1 is associated with ovarian cancer progression and chemoresistance.
    Liu, Dongli
    John, Miya
    Henry, Claire E.
    Christie, Elizabeth L.
    Bowtell, David D. L.
    Tang, Kristina
    Heinzelmann-Schwarz, Viola
    Kennedy, Catherine
    Boros, Jessica
    DeFazio, Anna
    Ford, Caroline E.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 59 - 60
  • [33] Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial
    Barbara A. Parker
    Rebecca A. Shatsky
    Richard B. Schwab
    Anne M. Wallace
    Denise M. Wolf
    Gillian L. Hirst
    Lamorna Brown-Swigart
    Laura J. Esserman
    Laura J. van ’t Veer
    Emanuela M. Ghia
    Christina Yau
    Thomas J. Kipps
    Breast Cancer Research and Treatment, 2023, 199 : 281 - 291
  • [34] Wnt5a induces ROR1 and ROR2 to activate RhoA in esophageal squamous cell carcinoma cells
    Wu, Xuping
    Yan, Ting
    Hao, Leiyu
    Zhu, Yichao
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 2803 - 2815
  • [35] Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial
    Parker, Barbara A.
    Shatsky, Rebecca A.
    Schwab, Richard B.
    Wallace, Anne M.
    Wolf, Denise M.
    Hirst, Gillian L.
    Brown-Swigart, Lamorna
    Esserman, Laura J.
    van 't Veer, Laura J.
    Ghia, Emanuela M.
    Yau, Christina
    Kipps, Thomas J.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (02) : 281 - 291
  • [36] ROR1 and ROR2-novel targets for neuroblastoma
    Dave, Hema
    Butcher, Donna
    Anver, Miriam
    Bollard, Catherine M.
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2019, 36 (06) : 352 - 364
  • [37] Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2
    O'Connell, Michael P.
    Marchbank, Katie
    Webster, Marie R.
    Valiga, Alexander A.
    Kaur, Amanpreet
    Vultur, Adina
    Li, Ling
    Herlyn, Meenhard
    Villanueva, Jessie
    Liu, Qin
    Yin, Xiangfan
    Widura, Sandy
    Nelson, Janelle
    Ruiz, Nivia
    Camilli, Tura C.
    Indig, Fred E.
    Flaherty, Keith T.
    Wargo, Jennifer A.
    Frederick, Dennie T.
    Cooper, Zachary A.
    Nair, Suresh
    Amaravadi, Ravi K.
    Schuchter, Lynn M.
    Karakousis, Giorgos C.
    Xu, Wei
    Xu, Xiaowei
    Weeraratna, Ashani T.
    CANCER DISCOVERY, 2013, 3 (12) : 1378 - 1393
  • [38] The role of Ror1 receptor in cancer
    Lopez Bergami, Pablo
    ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2011, 45 (04): : 665 - 668
  • [39] ROR2 Expression in Breast Cancer
    Guo, X.
    Sweeny, P.
    Varma, S.
    Montgomery, K.
    West, R. B.
    van de Rijn, M.
    MODERN PATHOLOGY, 2013, 26 : 45A - 45A
  • [40] ROR2 Expression in Breast Cancer
    Guo, X.
    Sweeny, P.
    Varma, S.
    Montgomery, K.
    West, R. B.
    van de Rijn, M.
    LABORATORY INVESTIGATION, 2013, 93 : 45A - 45A
12345